157 related articles for article (PubMed ID: 12720497)
1. Implications of the LIFE trial.
Nadar S; Lim HS; Lip GY
Expert Opin Investig Drugs; 2003 May; 12(5):871-7. PubMed ID: 12720497
[TBL] [Abstract][Full Text] [Related]
2. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
4. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Devereux RB; Dahlöf B; Kjeldsen SE; Julius S; Aurup P; Beevers G; Edelman JM; de Faire U; Fyhrquist F; Helle Berg S; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
Ann Intern Med; 2003 Aug; 139(3):169-77. PubMed ID: 12899584
[TBL] [Abstract][Full Text] [Related]
5. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Kizer JR; Dahlöf B; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Wachtell K; Edelman JM; Snapinn SM; Harris KE; Devereux RB
Hypertension; 2005 Jan; 45(1):46-52. PubMed ID: 15583076
[TBL] [Abstract][Full Text] [Related]
6. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B;
J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123
[TBL] [Abstract][Full Text] [Related]
7. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
9. [What are the consequences of the LIFE Study for general practice].
Zidek W
MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
[No Abstract] [Full Text] [Related]
10. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
Dominiak P; Zidek W
MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
[No Abstract] [Full Text] [Related]
11. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
12. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
13. [Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
MMW Fortschr Med; 2002 Sep; 144(38):14. PubMed ID: 12395694
[No Abstract] [Full Text] [Related]
14. Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Lyle PA
Expert Opin Pharmacother; 2004 Nov; 5(11):2311-20. PubMed ID: 15500378
[TBL] [Abstract][Full Text] [Related]
15. Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Ann Intern Med; 2003 Aug; 139(3):I28. PubMed ID: 12899605
[No Abstract] [Full Text] [Related]
16. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
17. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
18. [Results from the LIFE study: promising effects of new hypertensive agents].
Nilsson P; Kahan T
Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
[No Abstract] [Full Text] [Related]
19. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Franklin SS; Wachtell K; Papademetriou V; Olsen MH; Devereux RB; Fyhrquist F; Ibsen H; Kjeldsen SE; Dahlöf B
Hypertension; 2005 Sep; 46(3):492-9. PubMed ID: 16116047
[TBL] [Abstract][Full Text] [Related]
20. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
